328 related articles for article (PubMed ID: 6210188)
21. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
[TBL] [Abstract][Full Text] [Related]
22. Carbohydrate antigen (CA 19-9)--a valuable tumor marker of pancreatic cancer.
Lin JT; Wang TH; Sung JL; Chen DS
Taiwan Yi Xue Hui Za Zhi; 1985 Jul; 84(7):828-35. PubMed ID: 3864924
[No Abstract] [Full Text] [Related]
23. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
Röthlin M; Metzger U; Joller H; Largiadèr F
Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
[TBL] [Abstract][Full Text] [Related]
24. [Attention to CA 19.9 in alcoholics. Apropos of a case].
Giovannini M; Penalvert F; Maillot A; Escoffier JM; Botta D; Gauthier A
Ann Gastroenterol Hepatol (Paris); 1987 Dec; 23(7):393. PubMed ID: 3481241
[No Abstract] [Full Text] [Related]
25. [Monoclonal antibodies in the radioimmunological diagnosis of malignant tumors of the gastrointestinal tract and ovaries].
Tkacheva GA; Blokhina NG; Klimenkov AA; Kozachenko VP
Vopr Onkol; 1985; 31(5):36-42. PubMed ID: 2409674
[TBL] [Abstract][Full Text] [Related]
26. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
Harmenberg U; Wahren B; Wiechel KL
Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
Souchon R; Koppenhagen K; Souchon MF; Matthes M; Boese-Landgraf J; Fitzner R; Baer U
Cancer Detect Prev; 1985; 8(1-2):101-9. PubMed ID: 3864534
[TBL] [Abstract][Full Text] [Related]
28. [Significance of a new tumor marker (CA 19-9) in the differential diagnosis of pathological changes in the pancreas detected by ultrasonic diagnosis].
Bohár L; Szilvási I; Bodorné N; Varsányi N; Barda L; Sarkadi G
Orv Hetil; 1985 Oct; 126(41):2525-7. PubMed ID: 3900874
[No Abstract] [Full Text] [Related]
29. [Pancreatic oncofetal antigen (POA)].
Mugitani H; Furue H; Kako M; Hirota F; Fuse K; Takahashi T; Sakamoto K; Yamada K; Suminaga M; Ezaki M; Judo R
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1737-43. PubMed ID: 6882002
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of a monoclonal antibody (CA 19-9 system) in gastrointestinal disease--in comparison with CEA and IAP].
Furukawa M; Kozaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Nihon Gan Chiryo Gakkai Shi; 1985 Feb; 20(1):25-30. PubMed ID: 3858395
[No Abstract] [Full Text] [Related]
31. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
Van Gossum M; Delanghe A; Gerard M; Delcourt A; Deltenre M
Acta Gastroenterol Belg; 1987; 50(1):91-4. PubMed ID: 3480672
[No Abstract] [Full Text] [Related]
32. [Tumor markers in malignancies of the gastrointestinal tract].
von Kleist S; Hohneck A
Internist (Berl); 1982 Jan; 23(1):10-2. PubMed ID: 6175599
[No Abstract] [Full Text] [Related]
33. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
34. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
Yoshikawa T; Nishida K; Tanigawa M; Fukumoto K; Kondo M
Digestion; 1985; 31(2-3):67-76. PubMed ID: 2581838
[TBL] [Abstract][Full Text] [Related]
35. Immunological diagnosis and prognosis of digestive tract cancer: some clinical considerations.
Zamcheck N
Ann Immunol (Paris); 1973 Nov; 124(4):635-40. PubMed ID: 4792503
[No Abstract] [Full Text] [Related]
36. [Antigens associated with cancer of the pancreas].
Burtin P
Bull Cancer; 1990; 77(1):69-73. PubMed ID: 2317577
[TBL] [Abstract][Full Text] [Related]
37. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
38. [CA 19-9 in benign diseases of the gastrointestinal tract].
Klapdor R
Dtsch Med Wochenschr; 1986 Jun; 111(26):1039. PubMed ID: 3459644
[No Abstract] [Full Text] [Related]
39. [Oncofetal antigen].
Nishida K; Yoshikawa T; Kondo M
Nihon Rinsho; 1980; 38(1):152-60. PubMed ID: 6156250
[No Abstract] [Full Text] [Related]
40. Pancreatic oncofoetal antigen in pancreatic cancer.
Hobbs JR; Branfoot AC; Knapp ML
Practitioner; 1980 Oct; 224(1348):1023-7. PubMed ID: 7220429
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
